Repligen (NASDAQ:RGEN) Coverage Initiated at Canaccord Genuity Group

Canaccord Genuity Group started coverage on shares of Repligen (NASDAQ:RGEN) in a report released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a hold rating and a $165.00 price objective on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. Wolfe Research initiated coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Stock Performance

Repligen stock opened at $158.14 on Tuesday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The stock’s 50 day simple moving average is $143.15 and its two-hundred day simple moving average is $141.68. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market cap of $8.86 billion, a price-to-earnings ratio of -427.41, a PEG ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 earnings per share. As a group, analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Several large investors have recently modified their holdings of the company. First Turn Management LLC bought a new stake in shares of Repligen during the 3rd quarter valued at about $13,202,000. Geneva Capital Management LLC grew its position in Repligen by 8.5% during the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after buying an additional 10,908 shares during the period. Banque Pictet & Cie SA increased its holdings in Repligen by 74.6% during the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after buying an additional 14,746 shares during the last quarter. Thrivent Financial for Lutherans raised its position in Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after acquiring an additional 425,061 shares during the period. Finally, Integral Health Asset Management LLC boosted its stake in shares of Repligen by 20.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 60,000 shares of the biotechnology company’s stock worth $7,564,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.